Gary Stephens

Title: Innovations of Gary Stephens in Cannabinoid Research

Introduction

Gary Stephens is a prominent inventor based in Reading, GB, known for his significant contributions to the field of cannabinoid research. With a total of 11 patents to his name, he has focused on the therapeutic applications of phytocannabinoids, particularly in the treatment of epilepsy.

Latest Patents

One of his latest patents involves the use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) for treating epilepsy. This invention highlights the efficacy of CBD at doses greater than 300 mg/day, particularly when used alongside SAEDs that modulate sodium or calcium channels. Preferred SAEDs include ethosuximide and valproate, which are known to reduce high-frequency neuronal firing and enhance GABA effects. Another notable patent is a pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). This composition is designed for treating neurological conditions characterized by hyper-excitability of the central nervous system, such as epilepsy. It is particularly safe and effective, especially when combined with non-cannabinoid components like terpenes.

Career Highlights

Throughout his career, Gary has worked with notable companies such as GW Pharma Limited and Otsuka Pharmaceutical Company, Limited. His work has significantly advanced the understanding and application of cannabinoids in medical treatments.

Collaborations

Gary has collaborated with esteemed colleagues, including Claire Williams and Benjamin Whalley, contributing to the innovative research in cannabinoid therapies.

Conclusion

Gary Stephens continues to be a leading figure in cannabinoid research, with his inventions paving the way for new treatments in epilepsy and other neurological conditions. His work exemplifies the potential of cannabinoids in modern medicine.